Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Handling Genetically Modified Organisms (GMO) – V 2.0

Posted on By


Biosimilars: SOP for Handling Genetically Modified Organisms (GMO) – V 2.0


Standard Operating Procedure for Handling Genetically Modified Organisms (GMO) in Biosimilar Facilities

Department Biosimilars
SOP No. SOP/BS/037/2025
Supersedes SOP/BS/037/2022
Page No. Page 1 of 14
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for the safe handling, containment, documentation, and disposal of Genetically Modified Organisms (GMOs) used during biosimilar R&D and manufacturing, as per Indian and international biosafety regulations.

2. Scope

This SOP applies to all personnel involved in genetic engineering, cell line development, vector handling, and biosimilar process development involving GMO cell lines and expression systems.

3. Responsibilities

  • Biosafety Officer: Oversees GMO use, maintains approvals, ensures containment and incident response readiness.
  • Laboratory Personnel: Follow containment, PPE, waste handling, and documentation protocols while handling GMOs.
  • QA Officer: Ensures compliance with GMO regulations and maintenance of GMO inventory and training records.

4. Accountability

The Head of Research & Development is accountable for ensuring institutional compliance with GMO handling guidelines and ensuring approvals from relevant authorities (e.g., IBSC, RCGM).

5. Procedure

5.1 GMO Risk Categorization

  1. Classify GMOs into Risk Category I, II, or III as per Indian Biosafety Rules, 1989.
  2. Maintain classification record for each new construct (Annexure-1).

5.2 Containment Requirements

  1. Ensure all GMO manipulations are conducted in BSL-2 certified facilities.
  2. Work inside certified biosafety cabinets (Class II A2) during:
    • Transformation/transfection
    • Cell banking and media manipulations
    • Harvesting and purification
  3. Maintain daily log of cabinet decontamination and use (Annexure-2).

5.3 Transport of GMOs

  1. Label GMO materials with:
    • GMO ID
    • Risk Category
    • Biohazard symbol
  2. Transport in triple containment packaging if transferring to external sites.
  3. Document transport in GMO Movement Log (Annexure-3).

5.4 Incident Reporting and Emergency Response

  1. In case of spills or containment breach:
    • Isolate area immediately
    • Disinfect with 1% sodium hypochlorite
    • Notify Biosafety Officer and document incident
  2. Complete GMO Incident Report (Annexure-4).

5.5 Waste Disposal

  1. Decontaminate all GMO waste by:
    • Autoclaving at 121°C, 15 psi, for 30 minutes
    • Incineration (if applicable)
  2. Dispose of according to BMW Rules, 2016 and CPCB guidelines.

5.6 Documentation and Records

  1. Maintain following logs:
    • GMO Register
    • Approval letters from IBSC/RCGM
    • GMO Movement Log
    • Training Records

6. Abbreviations

  • GMO: Genetically Modified Organism
  • IBSC: Institutional Biosafety Committee
  • RCGM: Review Committee on Genetic Manipulation
  • BSL-2: Biosafety Level 2

7. Documents

  1. GMO Classification Record (Annexure-1)
  2. Biosafety Cabinet Usage Log (Annexure-2)
  3. GMO Movement Log (Annexure-3)
  4. GMO Incident Report (Annexure-4)

8. References

  • Rules 1989 (under EPA Act) – Use of GMOs in India
  • WHO Laboratory Biosafety Manual (4th Ed.)
  • NIH Guidelines for Research Involving Recombinant DNA Molecules

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: GMO Classification Record

Date GMO ID Description Risk Category Classified By
02/05/2025 GMO-037-CHO CHO-K1 expressing mAb Category II Sunita Reddy

Annexure-2: Biosafety Cabinet Usage Log

Date Cabinet ID Decontaminated Used By Purpose
02/05/2025 BSC-03 Yes Rajesh Kumar GMO inoculation

Annexure-3: GMO Movement Log

Date GMO ID Sent To Transport Mode Container Type Remarks
02/05/2025 GMO-037-CHO QA Lab Hand Carry Triple Packed Internal transfer

Annexure-4: GMO Incident Report

Date Incident Location Immediate Action Reported By Corrective Action
01/05/2025 Spill inside BSC CLD Lab Bleach disinfection Ajay Verma Cabinet maintenance scheduled

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated for BSL-2 containment and triple packaging transport Regulatory enhancement
See also  Biosimilars: SOP for Audit Readiness of CLD Documentation - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Analytical Method Development: System Suitability Testing Parameters Design – V 2.0
Next Post: BA-BE Studies: SOP for Interim Clinical Monitoring Reports – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version